drugset / Trial / NCT04039516

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

NCT04039516

RandomizedParallel-groupOpen-labelTreatment

Summary

Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.

Timeline

Start
2020-10
Primary completion
2024-11
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTATATE Peptide 7400 mbq